Ayala Pharmaceuticals Inc (fka ADXS)

[fbg0316]

Agreed Smasse, $12 is the average recapitalization cost basis of the company in which investors poured more than $200 million over the last four years. Until management gets us back to that breakeven level, they don't deserve any bonus awards. Then let's see how much value they can create (i.e., on top of $12) to judge their effectiveness.